SLC5A2 and diabetes mellitus: In conclusion, combination therapy of DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin increased β-cell mass and enhanced β-cell function in an early phase of diabetes in diabetic db/db mice.